Month: May 2021

What is the Feds position on Crypto, Stablecoin, and CBDCs?

Posted on by Admin 

image credit: U.S. Federal Reserve


The Federal Reserve’s Discussion Paper on Digital Currency to be Released this Summer

 

Last week, Fed Chair Jerome Powell spoke in a video address about CBDCs (Central Bank Digital Currencies) and other cryptocurrencies. He announced the Federal Reserve plans to publish a discussion paper on the potential benefits and risks of issuing a U.S. digital currency during this summer.  He also shared more insight on current thinking.

“The paper represents the beginning of what will be a thoughtful and deliberative process,” said Chairman Powell in his address. He also spoke of regulation making it clear there were no decisions made to date when expressing the eye in which the Fed will look at the matter, “ the Federal Reserve is charged with promoting monetary and financial stability and the safety and efficiency of the payment system. In pursuit of these core functions, we have been carefully monitoring and adapting to the technological innovations now transforming the world of payments, finance, and banking.” Powell also made clear that one decision that has been made is that cash currency is not going away, “We think it is important that any potential CBDC could serve as a complement to, and not a replacement of, cash and current private-sector digital forms of the dollar, such as deposits at commercial banks,” said Powell.

A link for the video is provided below as a “Source,” but, as with most Fed releases, every word is deliberate and therefore worth reading. Here is the complete transcript.

 

Transcript of Chair Powell’s Message on Developments in the U.S. Payments System

May 20, 2021

Today we are in the midst of a technological revolution that is fundamentally changing our world: reshaping how we communicate, access information, and purchase goods and services. As the central bank of the United States, the Federal Reserve is charged with promoting monetary and financial stability and the safety and efficiency of the payment system. In pursuit of these core functions, we have been carefully monitoring and adapting to the technological innovations now transforming the world of payments, finance, and banking.

The effective functioning of our economy requires that people have faith and confidence not only in the dollar, but also in the payment networks, banks, and other payment service providers that allow money to flow on a daily basis. Our focus is on ensuring a safe and efficient payment system that provides broad benefits to American households and businesses while also embracing innovation. In the Fed’s early days, the development of dedicated telegraph wires facilitated the transfer of funds between banks. In the 1980s, automated clearinghouse services made it possible for electronic bill payments to be an alternative to paper checks. In 2019, the Federal Reserve committed to building the FedNow Service, which will enable banks to provide real-time, or instant, payments to their customers around the clock, 365 days a year, benefiting communities across America.

Recently, the rise of distributed ledger technology, which offers a new approach to recording ownership of assets, has allowed for the creation of a range of new financial products and services—including cryptocurrencies. To date, cryptocurrencies have not served as a convenient way to make payments, given, among other factors, their swings in value. Nonetheless, coins tied to the value of the dollar or another currency—known as “stablecoins”— have emerged as a new way to make payments. These stablecoins aim to use new technologies in a way that has the potential to enhance payments efficiency, speed up settlement flows, and reduce end-user costs—but they may also carry potential risks to those users and to the broader financial system. For example, although the value of a stablecoin may be tied to the value of a dollar, these coins may not come with the same protections as traditional means of payment, such as physical currency or the deposits in your bank account. Therefore, as stablecoins’ use increases, so must our attention to the appropriate regulatory and oversight framework. This includes paying attention to private-sector payments innovators who are currently not within the traditional regulatory arrangements applied to banks, investment firms, and other financial intermediaries.

Technological advances also offer new possibilities to central banks—including the Fed. In particular, technology now enables the development and issuance of central bank digital currencies, or CBDCs. A CBDC is a new type of central bank liability issued in digital form. While various structures and technologies might be used, a CBDC could be designed for use by the general public.

For the past several years, the Federal Reserve has been exploring the potential benefits and risks of CBDCs from a variety of angles, including through technological research and experimentation. Our key focus is on whether and how a CBDC could improve on an already safe, effective, dynamic, and efficient U.S. domestic payments system. We think it is important that any potential CBDC could serve as a complement to, and not a replacement of, cash and current private-sector digital forms of the dollar, such as deposits at commercial banks. The design of a CBDC would raise important monetary policy, financial stability, consumer protection, legal, and privacy considerations and will require careful thought and analysis— including input from the public and elected officials.

To help stimulate broad conversation, the Federal Reserve Board will issue a discussion paper this summer outlining our current thinking on digital payments, with a particular focus on the benefits and risks associated with CBDC in the U.S. context. As part of this process, we will ask for public comment on issues related to payments, financial inclusion, data privacy, and information security.

We are committed at the Federal Reserve to hearing a wide range of voices on this important issue before making any decision on whether and how to move forward with a U.S. CBDC, taking account of the broader risks and opportunities it could offer. The paper represents the beginning of what will be a thoughtful and deliberative process. Irrespective of the conclusion we ultimately reach, we expect to play a leading role in developing international standards for CBDCs, engaging actively with central banks in other jurisdictions as well as regulators and supervisors here in the United States throughout that process.

The Federal Reserve remains committed to ensuring that the public has access to a safe, reliable, and secure payments system. Our forthcoming paper on the evolution of digital payments is intended—along with our other work as a supervisor, regulator, and payment system operator—to advance the objective of ensuring that the payments system and the economy work for all Americans. We look forward to hearing your thoughts on this important topic.

 

 

Take-Away

In his announcement, Chairman Powell showed he understood how technology in the past has led to better communication, faster payment systems, and more efficient bank clearing operations. He also was clear that, to date, the experience with cryptocurrencies is that they do not serve as a convenient way to make payments, “given, among other factors, their swings in value.” Adopting new technologies such as distributed ledger systems and a stable payment system is the balance the Fed will likely try to create going forward.

We will know more when the discussion paper is released later this year; in the interim, cryptocurrency exchange rates are likely to move up and down on, among other things, speculation of the tone of the upcoming paper.


Suggested Reading:

Small-Cap Names in a Big Crypto Market

Backed by the Full Faith and Credit of Blockchain



Cryptocurrency and the Howey Test

NFTs are Becoming More Popular with Sports Fans


Sources:

Chairman Powell’s Video Message May 20, 2020

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

Posted on by Admin


Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

 

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is excited to announce that the Company’s subsidiary, CannMart Inc., holder of exclusive distribution rights to all Phyto Extractions™ products, is now distributing Phyto Extractions’ well known shatter products nationally for its medical consumers at CannMart.com, and distribution to recreational consumers via anticipated future sales to provincial monopoly wholesalers. This new launch will provide patients through CannMart.com the opportunity to purchase Phyto Extractions’ latest shatter product line in three strain varieties: Pink Kush, Blue Gorilla OG and D. Bubba, offering Canadians the opportunity of a renewed experience in the limited shatter offerings currently available in Canada. CannMart medical patients are easily able to purchase Phyto Extractions products from the comfort of their home and have them delivered directly to their door once they have received their medical document.

“We are pleased to offer cannabis consumers high quality shatter products from Phyto,” said Meni Morim, CEO of Namaste. “Shatter is a specialized subcategory of concentrate products, which is currently underserved, and has higher margins. The Phyto brand carries significant legacy cache when it comes to this subcategory, all combined, making this product expansion a compelling growth opportunity. While these products are available now for medical customers, we expect them to be available on the recreational market shortly. We have already received confirmations and approvals for SKUs in hand and purchase orders in process of finalization with certain provinces – all wanting this new product line available for their consumers.”

Phyto Extractions’ shatter is a well-known cannabis extract in its purest form, with over 70% THC, negligible CBD content, and a distinguishing effect that is said to outperform other extracts. Extracted with butane to preserve cannabis terpenes, both shatter’s fast-acting onset and natural derived terpenes that maintain and enhance the natural flavour of the extracted plant are unique selling points that are highly regarded by medical and recreational consumers. These products are anticipated to be available shortly via CannMart’s wholesale distribution channel in Alberta, Saskatchewan, Manitoba, British Columbia and Ontario to recreational customers, looking for a desirable experience with cannabis concentrates.

Producing pure extracts such as shatter, must be conducted in a controlled laboratory environment with strict safety measures. Phyto Extractions has recently upgraded its facility with the new ExtractionTek Solutions MeP XT70 hydrocarbon extraction system to ensure all shatter products are pure, safe and consistent with unmatched quality to maximize the consumer experience. For more information on how shatter is made, watch Phyto Extractions facility tour and shatter production process: https://youtu.be/bMz4V_WVoLI

About Phyto Extractions™

Phyto Extractions™ is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction and products, no cultivation), Sales (extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to distribution of products on cannmart.com and through CannMart provincial buyers are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, CannMart Inc.’s ability to finalize and fulfill purchase orders for shatter products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.

TherapeuticsMD Announces Submission of Low Dose BIJUVA Supplemental New Drug Application to FDA

Posted on by Admin


TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

 

BOCA RATON, Fla.–(BUSINESS WIRE)–May 25, 2021– 
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the 
U.S. Food and Drug Administration (“FDA”).

The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be within ten months of receipt by the FDA, approximately 
March 21, 2022.

“We are pleased to have identified a path forward for submission to the FDA of our sNDA for low-dose BIJUVA. We believe low-dose BIJUVA will be an important additional therapeutic option for women, if approved, and we look forward to bringing it to market,” said  Robert G. Finizio, Chief Executive Officer of 
TherapeuticsMD.

BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule. It is taken once-daily for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

About BIJUVA

BIJUVA is a novel combination of bio-identical estradiol and bio-identical progesterone in a once-daily oral softgel capsule. BIJUVA is approved in the 
U.S. in a 1mg/100mg strength for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

INDICATION

BIJUVA (estradiol and progesterone) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.

IMPORTANT SAFETY INFORMATION

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, and PROBABLE DEMENTIA

See full prescribing information for complete boxed warning.

Estrogen Plus Progestin Therapy

  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer
  • The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen-Alone Therapy

  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen-alone substudy reported increased risks of stroke and DVT
  • The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

CONTRAINDICATIONS

BIJUVA is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease (for example, stroke, MI), or a history of these conditions; known anaphylactic reaction, angioedema, or hypersensitivity to BIJUVA or any of its ingredients; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

WARNINGS AND PRECAUTIONS

  • An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. Should these occur or be suspected, therapy should be discontinued immediately. Risk factors for arterial vascular disease and/or venous thromboembolism (VTE) should be managed appropriately.
  • The WHI substudy of daily estrogen plus progestin after a mean follow-up of 5.6 years reported an increased risk of invasive breast cancer. Observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy after several years of use. The risk increased with duration of use and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). The use of estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.
  • Endometrial hyperplasia (a possible precursor to endometrial cancer) has been reported to occur at a rate of approximately less than one percent with BIJUVA. Clinical surveillance of all women using estrogen plus progestin therapy is important. Adequate diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
  • The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
  • In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin when compared to placebo. It is unknown whether these findings apply to younger postmenopausal women.
  • Estrogens increase the risk of gallbladder disease.
  • Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs.
  • Monitor thyroid function in women on thyroid replacement hormone therapy.

The most common adverse reactions (?3%) for BIJUVA are breast tenderness (10.4%), headache (3.4%), vaginal bleeding (3.4%), vaginal discharge (3.4%) and pelvic pain (3.1%).

Please note that this information is not comprehensive. Please see the Full Prescribing Information including BOXED WARNING at BIJUVA.com.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about 
TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: 
TherapeuticsMD.

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the FDA will accept and approve the NDA efficacy supplement for the lower dose of BIJUVA; the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by any such divestiture will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contacts
Nichol Ochsner
Vice President, Investor Relations
561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
lwilson@insitecony.com

Media Contact
Kristen Landon
Vice President, 
Marketing and Corporate Communications
561-961-1900
Klandon@therapeuticsmd.com

Source: 
TherapeuticsMD, Inc.

Release – Esports Entertainment Group to Add Swedish and Spanish-Licensed Gaming Business with Acquisition of Bethard

Posted on by Admin

 


Esports Entertainment Group to Add Swedish and Spanish-Licensed Gaming Business with Acquisition of Bethard

 

  • Bethard, the B2C business of Gameday Group plc, generated $31M net gaming revenues in 2020

  • GMBL raises Fiscal 2022 revenue guidance to $100M-$105M as result of the transaction

Newark, New Jersey–(Newsfile Corp. – May 25, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”), an esports entertainment and online gambling company, today announced the signing of an agreement to acquire Gameday Group’s B2C business, operating under the ‘Bethard’ brand by Bethard Group Limited (“Bethard”), a fast-growing sports betting operator that generated $31 million in revenue in 2020. Under the terms of the agreement, EEG will pay EUR 16 mil ($19.5 mil) in cash and a 12% net gaming revenue share for two years. The acquisition is expected to close on July 1, 2021. As a result of transaction, Esports Entertainment Group is raising its fiscal 2022 revenue guidance to $100 million to $105 million.

“This is another great addition for Esports Entertainment Group that substantially increases our revenues, and available markets,” commented Grant Johnson, CEO of Esports Entertainment Group. “With this transaction, we expect to gain two new gaming licenses, including one in the strategically important Swedish market. At the completion of the license hand over we will have 6 tier one licenses.”

Bethard is an iGaming company that offers sports betting and casino games online. The company was founded in 2012 and consists of a team of passionate individuals who shares a vision of taking sports betting and casino to the next level. Bethard has a strong focus on responsible gambling with best-in-class compliance functions in order to act properly and in a sustainable way in regulated markets. The company is based in St. Julians, Malta.

According to ResearchAndMarkets.com, the global gaming market reached a value of $167.9 billion in 2020 and is forecasted to grow at a 9.2% CAGR through 2026, reaching $287.1 billion.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com

Media & Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

Posted on by Admin


Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

 

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is excited to announce that the Company’s subsidiary, CannMart Inc., holder of exclusive distribution rights to all Phyto Extractions™ products, is now distributing Phyto Extractions’ well known shatter products nationally for its medical consumers at CannMart.com, and distribution to recreational consumers via anticipated future sales to provincial monopoly wholesalers. This new launch will provide patients through CannMart.com the opportunity to purchase Phyto Extractions’ latest shatter product line in three strain varieties: Pink Kush, Blue Gorilla OG and D. Bubba, offering Canadians the opportunity of a renewed experience in the limited shatter offerings currently available in Canada. CannMart medical patients are easily able to purchase Phyto Extractions products from the comfort of their home and have them delivered directly to their door once they have received their medical document.

“We are pleased to offer cannabis consumers high quality shatter products from Phyto,” said Meni Morim, CEO of Namaste. “Shatter is a specialized subcategory of concentrate products, which is currently underserved, and has higher margins. The Phyto brand carries significant legacy cache when it comes to this subcategory, all combined, making this product expansion a compelling growth opportunity. While these products are available now for medical customers, we expect them to be available on the recreational market shortly. We have already received confirmations and approvals for SKUs in hand and purchase orders in process of finalization with certain provinces – all wanting this new product line available for their consumers.”

Phyto Extractions’ shatter is a well-known cannabis extract in its purest form, with over 70% THC, negligible CBD content, and a distinguishing effect that is said to outperform other extracts. Extracted with butane to preserve cannabis terpenes, both shatter’s fast-acting onset and natural derived terpenes that maintain and enhance the natural flavour of the extracted plant are unique selling points that are highly regarded by medical and recreational consumers. These products are anticipated to be available shortly via CannMart’s wholesale distribution channel in Alberta, Saskatchewan, Manitoba, British Columbia and Ontario to recreational customers, looking for a desirable experience with cannabis concentrates.

Producing pure extracts such as shatter, must be conducted in a controlled laboratory environment with strict safety measures. Phyto Extractions has recently upgraded its facility with the new ExtractionTek Solutions MeP XT70 hydrocarbon extraction system to ensure all shatter products are pure, safe and consistent with unmatched quality to maximize the consumer experience. For more information on how shatter is made, watch Phyto Extractions facility tour and shatter production process: https://youtu.be/bMz4V_WVoLI

About Phyto Extractions™

Phyto Extractions™ is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction and products, no cultivation), Sales (extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to distribution of products on cannmart.com and through CannMart provincial buyers are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, CannMart Inc.’s ability to finalize and fulfill purchase orders for shatter products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.

Release – TherapeuticsMD Announces Submission of Low Dose BIJUVA Supplemental New Drug Application to FDA

Posted on by Admin


TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

 

BOCA RATON, Fla.–(BUSINESS WIRE)–May 25, 2021– 
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the 
U.S. Food and Drug Administration (“FDA”).

The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be within ten months of receipt by the FDA, approximately 
March 21, 2022.

“We are pleased to have identified a path forward for submission to the FDA of our sNDA for low-dose BIJUVA. We believe low-dose BIJUVA will be an important additional therapeutic option for women, if approved, and we look forward to bringing it to market,” said  Robert G. Finizio, Chief Executive Officer of 
TherapeuticsMD.

BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule. It is taken once-daily for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

About BIJUVA

BIJUVA is a novel combination of bio-identical estradiol and bio-identical progesterone in a once-daily oral softgel capsule. BIJUVA is approved in the 
U.S. in a 1mg/100mg strength for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

INDICATION

BIJUVA (estradiol and progesterone) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.

IMPORTANT SAFETY INFORMATION

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, and PROBABLE DEMENTIA

See full prescribing information for complete boxed warning.

Estrogen Plus Progestin Therapy

  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer
  • The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen-Alone Therapy

  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen-alone substudy reported increased risks of stroke and DVT
  • The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

CONTRAINDICATIONS

BIJUVA is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease (for example, stroke, MI), or a history of these conditions; known anaphylactic reaction, angioedema, or hypersensitivity to BIJUVA or any of its ingredients; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

WARNINGS AND PRECAUTIONS

  • An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. Should these occur or be suspected, therapy should be discontinued immediately. Risk factors for arterial vascular disease and/or venous thromboembolism (VTE) should be managed appropriately.
  • The WHI substudy of daily estrogen plus progestin after a mean follow-up of 5.6 years reported an increased risk of invasive breast cancer. Observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy after several years of use. The risk increased with duration of use and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). The use of estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.
  • Endometrial hyperplasia (a possible precursor to endometrial cancer) has been reported to occur at a rate of approximately less than one percent with BIJUVA. Clinical surveillance of all women using estrogen plus progestin therapy is important. Adequate diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
  • The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
  • In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin when compared to placebo. It is unknown whether these findings apply to younger postmenopausal women.
  • Estrogens increase the risk of gallbladder disease.
  • Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs.
  • Monitor thyroid function in women on thyroid replacement hormone therapy.

The most common adverse reactions (?3%) for BIJUVA are breast tenderness (10.4%), headache (3.4%), vaginal bleeding (3.4%), vaginal discharge (3.4%) and pelvic pain (3.1%).

Please note that this information is not comprehensive. Please see the Full Prescribing Information including BOXED WARNING at BIJUVA.com.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about 
TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: 
TherapeuticsMD.

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the FDA will accept and approve the NDA efficacy supplement for the lower dose of BIJUVA; the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by any such divestiture will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contacts
Nichol Ochsner
Vice President, Investor Relations
561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
lwilson@insitecony.com

Media Contact
Kristen Landon
Vice President, 
Marketing and Corporate Communications
561-961-1900
Klandon@therapeuticsmd.com

Source: 
TherapeuticsMD, Inc.

Esports Entertainment Group to Add Swedish and Spanish-Licensed Gaming Business with Acquisition of Bethard

Posted on by Admin

 


Esports Entertainment Group to Add Swedish and Spanish-Licensed Gaming Business with Acquisition of Bethard

 

  • Bethard, the B2C business of Gameday Group plc, generated $31M net gaming revenues in 2020

  • GMBL raises Fiscal 2022 revenue guidance to $100M-$105M as result of the transaction

Newark, New Jersey–(Newsfile Corp. – May 25, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”), an esports entertainment and online gambling company, today announced the signing of an agreement to acquire Gameday Group’s B2C business, operating under the ‘Bethard’ brand by Bethard Group Limited (“Bethard”), a fast-growing sports betting operator that generated $31 million in revenue in 2020. Under the terms of the agreement, EEG will pay EUR 16 mil ($19.5 mil) in cash and a 12% net gaming revenue share for two years. The acquisition is expected to close on July 1, 2021. As a result of transaction, Esports Entertainment Group is raising its fiscal 2022 revenue guidance to $100 million to $105 million.

“This is another great addition for Esports Entertainment Group that substantially increases our revenues, and available markets,” commented Grant Johnson, CEO of Esports Entertainment Group. “With this transaction, we expect to gain two new gaming licenses, including one in the strategically important Swedish market. At the completion of the license hand over we will have 6 tier one licenses.”

Bethard is an iGaming company that offers sports betting and casino games online. The company was founded in 2012 and consists of a team of passionate individuals who shares a vision of taking sports betting and casino to the next level. Bethard has a strong focus on responsible gambling with best-in-class compliance functions in order to act properly and in a sustainable way in regulated markets. The company is based in St. Julians, Malta.

According to ResearchAndMarkets.com, the global gaming market reached a value of $167.9 billion in 2020 and is forecasted to grow at a 9.2% CAGR through 2026, reaching $287.1 billion.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com

Media & Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

Essential Metals in the Health Sector

Posted on by Admin 

image credit: This is Engineering, (Flickr)


Rare Metals Play a Strategic and Essential Role in Health

 

The COVID-19 pandemic has highlighted the fact that most countries do not have sufficient health sovereignty to face such a crisis. Shortages of masks, respirators, medicines and now vaccines were felt in many countries, even the most advanced. These problems show that our societies are dependent on certain countries for essential products.


But what about metals?

Our research team has been working for a few years on the interactions between earth sciences and social sciences, especially around the concept of social geology and the dynamics of resource-rich territories.


Strategic Metals

The notion of critical and strategic minerals goes back to the wars of the 19th century. At the end of the Second World War, the United States built up stocks of metals. However, the overabundance of metals at the end of the 20th century and globalization led western states to abandon their proactive policy in this field. Awareness of dependence on imported mineral resources did not return until the late 1990s, with the emergence of Asian economies and new monopolies.

The list of critical and strategic metals varies from country to country, ranging from a dozen for the French National Defense to the 35 metals listed in the decree of President Donald Trump in 2018.

Why do we have these lists of metals? They reflect the major issues of the past, those of the wars of the 20th century and the conflicts feared for the future. More generally, they mark the technological and social crises that have hit our societies during the past 50 years and which have led to what the German sociologist Ulrich Beck has called the risk society.

Each crisis has left in its wake new technological solutions, secure supply chains and an increased awareness of the dependence on various metals. Here are a few examples.

 

From Oil to Gold

In 1973, the oil crisis highlighted the energy fragility of most developed countries. Some countries turned to nuclear power, others to hydroelectricity. Uranium mines were put into production everywhere, from Saskatchewan to Niger. The price of ore soared in 1978 and production peaked in 1980.

The terrorist crisis of 2001 in turn accelerated the development of information technology in the defence industries and the consumption of high-tech metals increased accordingly. The price of tantalum reached its highest point in 2000 and world production peaked in 2004. This demand encouraged artisanal production in eastern Congo, which has been a centre of conflict for 20 years.

The nuclear crises following the 1986 Chernobyl and 2011 Fukushima accidents encouraged a shift to metal-intensive renewable energies, particularly wind power. The price of rare-earth elements exploded to a peak in 2010 and production doubled in the following decade.

Finally, in 2008, the financial crisis weakened global markets and led to a resumption of gold purchases, particularly by the Russian and Chinese central banks, which helped support the price of the precious metal.

It is therefore understandable that each crisis is accompanied by new needs in minerals and the need to secure these new metal sectors.


Metals and Health Issues

Metals have been used for human health for thousands of years. Ayurveda, a traditional medicine that has been practiced for 3,000 years in India, employs lead, mercury and arsenic to treat various ailments. Toxic in excessive quantities, these metals can, however, become indispensable in certain medicines and medical and orthopedic equipment.

Today, pharmacology uses more than a dozen metals or metalloids for various conditions: iron for anemia, bismuth, cobalt and nickel for gastric problems, lithium for depression, antimony for leishmaniasis, platinum or radioactive metals for cancer, arsenic for psoriasis. Gold can even help with the treatment of rheumatoid arthritis.

Metals are also widely used in prostheses: a mouth treated by a dental technician could contain up to 32 different metals! Medical imaging also uses many metals, from X-rays to nuclear medicine. Nuclear magnetic resonance (NMR) is based on rare-earth magnets, while 20 per cent of the world’s gadolinium is used for solutions that increase the contrast of NMR images.

 

 

Metals and the COVID-19 Crisis

And COVID-19? Metals are found in both the prevention and treatment of this new disease.

Copper has been a favorite for creating anti-microbial surfaces, which can reduce hospital outbreaks and kill viruses and bacteria in less than two hours. Zinc can boost the immune system and has already been used against viruses.

Thus, in addition to strategic metals at the heart of conflicts, there are
metals that are essential to health. The COVID-19 pandemic caused shortages of
hygiene and pharmaceutical products. Advanced medical equipment, full of
electronic components and therefore high-value metals, was sometimes lacking.

Most western countries depend on imported metals. It is therefore time to seriously discern what is really indispensable, what essential metals are in the health sector and how to guarantee their supply for use in the next health crises.

 

This article
was republished with permission from The
Conversation, a news site dedicated to sharing ideas
from academic experts.  Written by:

Michel Jébrak, Professeur émérite en ressources minérales, Université du Québec à Montréal (UQAM)

Jack-Pierre Piguet

Professeur, Laboratoire GeoRessources,
Université de Lorraine

Yann Gunzburger

Professeur des universités, laboratoire GeoRessources, Université de Lorraine

 

Suggested Content:

Pros and Cons of FDA Funded In Part by Companies

The Sustainability of Growing Margin Debt



NobleCon Healthcare Panel Discussion (Video)

NobleCon Natural Resources Panel Discussion (Video)

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Aurania Confirms Significant Amounts Of High-Tech Metals In Tiria-Shimpia Samples

Posted on by Admin


Aurania Confirms Significant Amounts Of High-Tech Metals In Tiria-Shimpia Samples

 

Toronto, Ontario, May 25, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports that laboratory assays have confirmed the presence of the high-tech metals, gallium (“Ga”) and indium (“In”) in significant amounts in rock-chip samples from the Tiria-Shimpia target in the Company’s Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.

Gallium and indium are known to substitute for zinc in the structure of sphalerite (zinc sulphide mineral), and sulphidic zinc ores are a major source of these by-product metals.  Because of the growing usage in certain high-tech applications such as smartphones and solar cells, they are rapidly becoming economically important, and supply security-related concerns are reflected in their identification as critical raw materials.  Gallium is used in gallium arsenide (“GaAs”) semiconductor chips, and its unique properties enable electrons to pass through faster than in conventional silicon chips.  It is used to support 5G technologies.

Next generation GaAs semiconductors promise to bring a huge market, not totally replacing the existing semiconductor market, but ultimately making a huge dent in it. The ability to replace silicon semiconductors, a market that is $500 billion dollars in 2020 makes one sit up and take notice. The existing silicon semiconductor market is a pretty good size for a market that barely existed in 1975. Next generation GaAs support the signal speed that is needed to implement 5G. (Business Wire, March 4, 2020).

It has been well-publicized that there is currently a worldwide shortage of GaAs semiconductor chips.  Partly this is due to shutdown of bauxite mining operations in Shanxi province in China in 2019, due to environmental concerns, where gallium is produced as a by-product of alumina.  Bauxite from outside of China typically does not contain recoverable levels of gallium: https://roskill.com/news/gallium-price-floor-set-to-rise-in-2021. Whatever the situation, it would appear that gallium supply is inelastic.

So far, sampling at Tiria-Shimpia has produced maximum values of 163 parts per million (“ppm”) for gallium and 39 ppm for indium.  These high values are associated with high silver and zinc grades in rock-chip samples (Table 1).  According to Kitco Metals (https://www.kitco.com/strategic-metals/), the gallium price has ranged between approximately US$200 to US$534 per kilogram (“kg”) over the past five years.  The Indium price is reported by Kitco Metals to US$290 to US$490 per kg over the past five years.

It should be made clear that the Company has not performed any metallurgical testing to date to determine the extent to which these metals are recoverable in any quantity, if at all.

About the Area

Gallium and indium values are concentrated in the central part of the Tiria-Shimpia target in an area approximately 500 metres long, that remains open to the south. Elevated gallium and indium are found in crackle-brecciated limestone that contains veins of sphalerite and barite, associated with high values in silver and zinc reported in prior press releases dated May 21, 2021.

Table 1. Summary of rock-chip samples from the Shimpia central area.

Sample Number Gallium Indium Silver Zinc
(g/t) (g/t) (g/t) (%)
Y993462 163 9.6 43.8 37.0
E797971 160 38.6 6.3 25.9
Y992200 154 14.9 56.8 49.1
Y993461 132 33.7 73.4 40.3
Y992199 109 0.9 31.1 40.2
Y993454 31 5.9 4.9 15.2

Sample Analysis & Quality Assurance / Quality Control (“QAQC”)

Laboratories: The rock samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.

Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% copper and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

 Dr. Richard Spencer

President

Aurania Resources Ltd.

(416) 367-3200

richard.spencer@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Seanergy Maritime (SHIP) – Another Acquisition Increases Cape Exposure

Posted on by Admin

Tuesday, May 25, 2021

Seanergy Maritime (SHIP)
Another Acquisition Increases Cape Exposure

Seanergy Maritime Holdings Corp., an international shipping company, provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of 10 Capesize vessels, with total capacity of approximately 1,748,581 dwt and an average fleet age of about 9.8 years. The Company is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and class A warrants under “SHIPW”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another acquisition moves pro forma Cape fleet to 16. A 2012-built Cape, the Worldship, will be acquired for $33.7 million in 3Q2021. The Worldship has a scrubber and BWTS and a survey should be completed prior to delivery so downtime should be limited over the next two years. Combined with the Tradership and Patriotship, recent acquisitions total $135 million. Debt/lease financing of ~$48 million has been lined up or in process and existing cash should fund the remainder of the acquisition cost. If additional financing is required, flexibility is good since the Worldship, Patriotship and Hellaship should be unencumbered.

    Increasing 2021 EBITDA estimate to $77.1 million based on TCE rates of $26.8k/day versus our prior estimate of $75.4 million based on TCE rates of $26.8/day to reflect new acquisition.  Current 2H2021 Cape FFA rates are holding above $30.0k/day and most of the Capes are working on charters at indexed rates. While FFAs were fixed on four Capes earlier this year at lower TCE rates, we view the new …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Esports Entertainment Group (GMBL) – Jersey Shores Up Its Gambling Strategy

Posted on by Admin

Tuesday, May 25, 2021

Esports Entertainment Group, Inc. (GMBL)
Jersey Shores Up Its Gambling Strategy

Esports Entertainment Group Inc is a development-stage online gambling company focused purely on esports. The company’s principal business operations include design, develop and test wagering systems.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Jersey accepts gaming license. The company received the long-awaited, approval from New Jersey Division of Gaming Enforcement of its gaming license. While the approval does not distinguish between sports and esports betting, the company entered its application with one of the largest states for gambling in an effort to become the preeminent platform for esports betting.

    Next steps.  The company’s Vie gambling software platform will go through regulatory testing labs to determine if the software is compliant and meets regulatory standards. The testing could take approximately 3 to 10 weeks. Once the software is audited, the company could then be granted a transactional waiver. This will allow it to be in business and for customers to begin placing bets as soon as …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Supermoon! Red Blood Lunar Eclipse! It’s all Happening Tonight – Here is what it Means

Posted on by Admin 

image credit: Tomruen/WikimediaCommons, CC BY-SA


Supermoon! Red Blood Lunar Eclipse! It’s all Happening Tonight – Here is what it Means

 

The first lunar eclipse of 2021 is going to happen during the early hours of May 26. But this is going to be an especially super lunar event, as it will be a supermoon, a lunar eclipse and a red blood moon all at once. So what does this all mean?

The Moon appears 12% bigger when it is closest to Earth compared with its appearance when it’s farthest away

 

What’s a super moon?

A supermoon occurs when a full or new moon coincides with the Moon’s closest approach to the Earth.

The Moon’s orbit is not a perfect circle as it slowly rotates around Earth. Rfassbind/WikimediaCommons

The Moon’s orbit around Earth is not perfectly circular. This means the Moon’s distance from Earth varies as it goes around the planet. The closest point in the orbit, called the perigee, is roughly 28,000 miles closer to Earth than the farthest point of the orbit. A full moon that happens near the perigee is called a supermoon.

So why is it super? The relatively close proximity of the Moon makes it seem a little bit bigger and brighter than usual, though the difference between a supermoon and a normal moon is usually hard to notice unless you’re looking at two pictures side by side.

The phases of the Moon correspond to how much of the lit–up side you can see from Earth. Orion 8/WikimediaCommons, CC BY-SA

 

How does a lunar eclipse work?

A lunar eclipse happens when the Earth’s shadow covers all or part of the Moon. This can only happen during a full moon, so first, it helps to understand what makes a full moon.

Like the Earth, half of the Moon is illuminated by the sun at any one time. A full moon happens when the Moon and the Sun are on opposite sides of the Earth. This allows you see the entire lit-up side, which looks like a round disc in the night sky.

If the Moon had a totally flat orbit, every full moon would be a lunar eclipse. But the Moon’s orbit is tilted by about 5 degrees relative to Earth’s orbit. So, most of the time a full moon ends up a little above or below the shadow cast by the Earth.

A lunar eclipse occurs when the Moon passes through Earth’s shadow. Sagredo/WikimediaCommons

But twice in each lunar orbit, the Moon is on the same horizontal plane as both the Earth and Sun. If this corresponds to a full moon, the Sun, the Earth and the Moon will form a straight line and the Moon will pass through the Earth’s shadow. This results in a total lunar eclipse.

To see a lunar eclipse, you need to be on the night side of the Earth while the Moon passes through the shadow. The best place to see the eclipse on May 26, 2021, will be the middle of the Pacific Ocean, Australia, the East Coast of Asia and the West Coast of the Americas. It will be visible on the eastern half of the U.S., but only the very earliest stages before the Moon sets.

The Earth’s atmosphere gives the Moon a blood-red glow during total lunar eclipses. Irvin Calicut/WikimediaCommons, CC BY-SA

 

Why does the moon look red?

When the Moon is completely covered by Earth’s shadow it will darken, but doesn’t go completely black. Instead, it takes on a red color, which is why total lunar eclipses are sometimes called red or blood moons.

Sunlight contains all colors of visible light. The particles of gas that make up Earth’s atmosphere are more likely to scatter blue wavelengths of light while redder wavelengths pass through. This is called Rayleigh scattering, and it’s why the sky is blue and sunrises and sunsets are often red.

In the case of a lunar eclipse, red light can pass through the Earth’s atmosphere and is refracted – or bent – toward the Moon, while blue light is filtered out. This leaves the moon with a pale reddish hue during an eclipse.

Hopefully you will be able to go see this super lunar eclipse. When you do, now you will know exactly what makes for such a special sight.

 

This article was republished with permission from The
Conversation, a news
site dedicated to sharing ideas from academic experts.  Written by Shannon Schmoll Director, Abrams Planetarium, Department of Physics and Astronomy, Michigan State University

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Chakana Advances Resource Definition Drilling With Multiple High-Grade Intercepts

Posted on by Admin


Chakana Advances Resource Definition Drilling With Multiple High-Grade Intercepts

 

Soledad Project Highlights Include:

  • Huancarama East – four holes with high-grade intercepts, including 134.3m of 0.92 g/t Au, 0.86% Cu, and 80.7 g/t Ag (2.15% Cu-eq) from 119.7m depth;
  • Paloma East – five holes with strong grades, including 126.1m of 0.91 g/t Au, 0.20% Cu, and 11.6 g/t Ag (0.89% Cu-eq) starting at surface;
  • Paloma West – two holes with high grades, including 101.0m of 0.53 g/t Au, 1.01% Cu, and 41.5 g/t Ag (1.71% Cu-eq) starting at surface.

Vancouver, B.C., May 25, 2021 – Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), is pleased to provide results from eleven in-fill holes totaling 2,873.7m from the Huancarama, Paloma East, and Paloma West tourmaline breccia pipe discoveries at its Soledad project, Ancash, Peru (Table 1). Drilling continues as part of a fully-funded 26,000m exploration and resource drilling program planned for 2021 (Fig. 1).

David Kelley, President and CEO commented, “The resource definition drilling portion of our current program is going exceptionally well with excellent results from the three discoveries at Soledad since the resumption of drilling in 2020. Huancarama and Paloma West continue to demonstrate their high-grade nature, and strong grades were also encountered at Paloma East. Mineralization in all three breccia pipes starts at surface and is open at depth. These results are another positive step toward our resource estimate due out later this year that will include multiple breccia pipes. To date, we have only tested 15 out of the 110 total targets on the property.”

Resource Definition Drilling

Table 1. Mineralized intervals from resource definition drilling at Huancarama, Paloma East, and Paloma West.

DDH # FROM     –     TO (M) CORE LENGTH (M) AU
G/T		 AG
G/T		 CU % CU-EQ
%*		 AU-EQ G/T*
Huancarama East
SDH21-189  119.70  254.00  134.30  0.92  80.7 0.86 2.15 3.29
and 271.00  310.00  39.00  0.61  52.4 0.88 1.73 2.64
SDH21-193  29.20  38.80  9.60  1.35  78.8     2.38
and 110.00 273.00 163.00 0.26 20.1 0.43 0.77 1.18
SDH21-194 21.90 25.70 3.80 0.17 77.3 0.23 1.00 1.53
and 120.00 244.00 124.00 0.33 29.5 0.63 1.10 1.68
and 301.00  308.10  7.10  1.81  36.7 0.81 2.31 3.53
SDH21-198  144.00  210.00  66.00  0.99  82.6 1.01 2.36 3.62
including 166.00 197.00 31.00 1.46 149.9 1.77 4.01 6.13
Paloma East
SDH21-190 0.00 126.10 126.10 0.91 11.6 0.20 0.89 1.37
including 21.00 38.00 17.00 5.09 15.7     5.30
SDH21-191 0.00 99.40 99.40 0.62 12.5 0.31 0.82 1.26
and 144.00 198.70 54.70 0.16 13.9 0.22 0.44 0.68
SDH21-192 64.90 124.00 59.10 0.27 7.5 0.42 0.66 1.01
and 198.00 224.00 26.00 0.21 33.3     0.65
SDH21-195 53.00 121.00 68.00 0.28 7.3 0.31 0.56 0.85
SDH21-196 67.00 121.00 54.00 0.20 9.0 0.74 0.95 1.45
Paloma West
SDH21-197 27.00 84.80 57.80 0.53 69.4 1.17 2.11 3.23
including 28.20 49.00 20.80 1.06 183.8 2.32 4.58 7.01
SDH21-199 0.00 101.00 101.00 0.53 41.5 1.01 1.71 2.62
including 31.25 50.00 18.75 1.07 141.8 3.29 5.20 7.96

* Cu_eq and Au_eq values were calculated using copper, gold, and silver. Metal prices utilized for the calculations are Cu – US$2.90/lb, Au – US$1,300/oz, and Ag – US$17/oz. No adjustments were made for recovery as the project is an early-stage exploration project and metallurgical data to allow for estimation of recoveries are not yet available. The formulas utilized to calculate equivalent values are Cu-eq (%) = Cu% + (Au g/t * 0.6556) + (Ag g/t * 0.00857) and Au-eq (g/t) = Au g/t + (Cu% * 1.5296) + (Ag g/t * 0.01307).

Huancarama East

Four holes were drilled through the Huancarama East breccia pipe from step-out platforms (Figs. 2 and 3). One hole was drilled to the northeast, and three holes were drilled from east to west. All four holes intersected mineralized breccia, consistent with previous exploration holes (see news releases dated January 12, January 25, February 9, March 3, and April 28, 2021) with depths ranging between approximately 80m to 300m below surface. The breccia pipe has approximate lateral dimensions of 100m by 60m and is open at depth. Additional infill holes have been drilled, with more planned once assay results have been received.  Examples of mineralized drill core from these holes are shown in Figure 4.

Paloma East and Paloma West

The Paloma breccia pipes are located 300m north of Huancarama and are partially exposed at surface (Fig. 3). Five holes were drilled at Paloma East. Three holes were collared on the west side of the breccia pipe and drilled to the east, northeast, and southeast, and two holes were drilled from the north side of the exposed breccia pipe and oriented southwest and south. Mineralization was encountered in all five drill holes over a vertical range from surface to approximately 200m depth. Two resource definition holes were drilled at Paloma West from a platform on the northeast side of the exposed breccia pipe and drilled to the southwest. High-grade mineralization was intersected in both drill holes with depths ranging between approximately 20m to 80m below surface. Breccia in both pipes is open at depth and results presented here are consistent with previously reported results (see news releases dated September 17, October 26, November 18, December 3, and December 16, 2020; and April 28, 2021). Additional infill holes have been drilled at Paloma West with results pending.  Examples of mineralized drill core from these holes are shown in Figure 4.

2021 Resource and Exploration Drill Program

Results reported here are part of the fully funded 2021 drill program of 26,000m.  Combined with the drilling in the second half of 2020, approximately 32,000m is anticipated through 2021. Of this, 13,946.2m have been reported in 67 drill holes for the Paloma and Huancarama areas.  Within the 26,000m of drilling planned in 2021, the Company will complete approximately 16,000m of resource definition in-fill drilling. The results of this drill program are important to increase confidence in the resource estimate, anticipated later in 2021.

Additionally, 10,000m of exploration drilling is planned for 2021. This will focus on new targets located in the northern portion of the project that have not been drilled previously but are strategic to any eventual development at Soledad. Exploration targets have been ranked based on their technical merit, access, and logistics.

About Chakana Copper

Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of high-grade gold-copper-silver mineralization hosted in tourmaline breccia pipes. A total of 47,736 metres of exploration and resource definition drilling has been completed to date, testing 15 of 110 total exploration targets, confirming that Soledad is a large, well-endowed mineral system with strong exploration upside.  Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver. For more information on the Soledad project, please visit the website at www.chakanacopper.com.

Sampling and Analytical Procedures

Chakana follows rigorous sampling and analytical protocols that meet or exceed industry standards. Core samples are stored in a secured area until transport in batches to the ALS facility in Callao, Lima, Peru.  Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24.  Over limit silver, copper, lead and zinc are analyzed using the OG-46 procedure. Soil samples are analyzed by 4-acid (ME-MS61) and for gold by Fire Assay on a 30g sample (Au-ICP21).

Results of previous drilling and additional information concerning the Project, including a technical report prepared in accordance with National Instrument 43-101, are made available on Chakana’s SEDAR profile at www.sedar.com.

Qualified Person
David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101, reviewed and approved the technical information in this news release.

ON BEHALF OF THE BOARD
(signed) “David Kelley”
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone:   647 964 0292
Email:    jjobin@chakanacopper.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statement Advisory: This release may contain forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Chakana to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, the interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the “Project”), the potential to expand the mineralization, and to develop and grow a resource within the Project, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our belief in the potential for mineralization within unexplored parts of the Project. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward- looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.


Figure 1 – View looking north showing breccia pipes and occurrences within the northern Soledad cluster. Pipes that have been drilled in previous campaigns are shown in red. Outcropping breccia pipes shown in green are the focus of the current drill campaign. Other pipes and occurrences remain to be tested by drilling. Additional breccia pipes occur on the south half of the property and are not shown here.  


Figure 2 – Map of Paloma and the Huancarama Breccia Complex showing drill holes reported in this release, outcropping tourmaline breccias (dark red shapes), and modeled breccia pipes (light red shapes) based on all drill holes (previous drilling shown by dark gray traces). Light gray contours are 10m interval. Untested outcropping targets are also shown. Location of section line (A-A’) for Figure 3 indicated.


Figure 3 – Isometric view looking west highlighting the drill holes at Huancarama and Paloma reported in this release. Light red 3D shapes show preliminary shape of breccias based on all drill holes (see Figure 2).

Figure 4 – Select core photos from Huancarama, Paloma East, and Paloma West reported in this release: SDH21-189 (126.2m) mosaic and jigsaw tourmaline breccia with sulfide cement; SDH21-194 (125.15m) mosaic breccia with selective clast replacement by chalcopyrite and pyrite; SDH21-194 306.75m tourmaline breccia with late chalcopyrite replacement along vein; SDH21-190 (76.72m) tourmaline breccia with chalcopyrite filling open space; SDG21-190 (110.80) shingle breccia with selective chalcopyrite replacement of shingle clasts; SDH21-197 (42.8m) mosaic tourmaline breccia with selective clast replacement and open space filling by chalcopyrite and pyrite. Core diameter is 6.35cm (HQ) in all instances.